A randomised, multi-center, phase II study to investigate the safety and efficacy of SDX-101 (R-etodolac) in combination with chlorambucil, and that of chlorambucil alone, in patients with chronic lymphocytic leukemia

Trial Profile

A randomised, multi-center, phase II study to investigate the safety and efficacy of SDX-101 (R-etodolac) in combination with chlorambucil, and that of chlorambucil alone, in patients with chronic lymphocytic leukemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2012

At a glance

  • Drugs SDX 101 (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Cephalon; Salmedix
  • Most Recent Events

    • 08 Jun 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 08 Jun 2012 Actual patient number is 88 as reported by ClinicalTrials.gov.
    • 08 Jun 2012 Actual end date (1 Feb 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top